Portfolio Manager Factsheet

December 2015

The largest contributor to December performance, like November, was the mid-tier Japanese pharmaceutical company, Ono Pharmaceutical Co. Ltd. The company has been a leader in the immuno-oncology revolution with the global launches of Opdivo (nivolumab) for the treatment of cancer. Only one security created more than 15 basis points of negative contribution on an individual basis – Bluebird Bio Inc. The stock fell after the company released data for their lead pipeline candidate that disappointed investors.

Read more »

Register for email alerts

Worldwide Healthcare Trust PLC conducts its affairs so that its shares can be recommended by independent financial advisers (IFAs) to retail private investors. The shares are excluded from the Financial Conduct Authority's (FCA's) restrictions which apply to non-mainstream investment products because they are shares in a UK-listed investment trust.